Rosenson, Robert S.
Daviglus, Martha L.
Handelsman, Yehuda
Pozzilli, Paolo
Bays, Harold
Monsalvo, Maria Laura
Elliott-Davey, Mary
Somaratne, Ransi
Reaven, Peter
Funding for this research was provided by:
Amgen Inc. (N/A)
Article History
Received: 20 November 2018
Accepted: 18 February 2019
First Online: 5 April 2019
Duality of interest
: RSR reports: research grants to his institution from Akcea, Amgen, AstraZeneca, CVS Caremark, The Medicines Company, Regeneron and Sanofi; advisory boards for Amgen, Regeneron and Sanofi; honoraria from Akcea, Kowa and Pfizer; stock holdings in MediMergent; and royalties from UpToDate Inc. Neither HB nor his affiliated research centre own pharmaceutical stocks or patents. In the past 12 months, HB’s research site has received research grants from Amarin, Amgen, Alere, Allergan, Arisaph, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis, Dr. Reddy’s, Eisai, Elcelyx, Lilly, Esperion, Ferrer/Chiltern, Gemphire, Gilead, GlaxoSmithKline, iSpecimen, Janssen, Johnson & Johnson, Kowa, Merck, Nektar, Nichi-Iko, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Selecta, Takeda and TIMI. In the past 12 months, HB has served as a consultant/advisor for Alnylam, Akcea, Amgen, AstraZeneca, Eisai, Lilly, Esperion, Ionis (ISIS), Janssen, Johnson & Johnson, Kowa, Merck, Novartis, ProSciento, Regeneron and Sanofi. In the past 12 months, HB has served as a speaker for Amarin, Amgen, Eisai, Kowa, Orexigen, Regeneron and Sanofi. MLD is a member of the Repatha LCM Scientific Advisory Board. MLM is currently employed by Amgen Inc. and holds Amgen stock/stock options. ME-D is currently employed by Amgen Ltd. and holds Amgen stock/stock options. PP reports: advisory board/lecture honoraria from Lilly, Sanofi and MSD; participation in clinical trials for Lilly, Janssen, Lexicon, AstraZeneca, MSD, Boehringer Ingelheim and GlaxoSmithKline; and research funding or grants from Lilly, MSD, Sanofi, AstraZeneca, Lexicon and Janssen. RS was previously employed by Amgen, holds Amgen stock/stock options and is an inventor on at least one pending patent application owned by Amgen Inc. related to evolocumab. YH reports research grants and consultant and speaker honoraria from Aegerion, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Boehringer Ingelheim–Lilly, Eisai, Gan & Lee, Grifols, Hanmi, Intarcia, Janssen, Lexicon, Lilly, Merck, Merck-Pfizer, Novo Nordisk, Regeneron and Sanofi. PR reports: research grants from Novo Nordisk and (in the past 12 months) grants from Bristol-Myers Squibb; and consulting with Sanofi.